These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8583382)

  • 21. Intranasal administration of human fibroblast interferon in mice, rats, rabbits and dogs.
    Igawa T; Maitani Y; Machida Y; Nagai T
    Chem Pharm Bull (Tokyo); 1990 Feb; 38(2):549-51. PubMed ID: 2337971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absorption of acetylsalicylic acid from the rat nasal cavity.
    Hussain AA; Iseki K; Kagoshima M; Dittert LW
    J Pharm Sci; 1992 Apr; 81(4):348-9. PubMed ID: 1501071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The lymphatic route. VII. Distribution of recombinant human interleukin-2 in rabbit plasma and lymph.
    Bocci V; Pessina GP; Nicoletti C; Paulesu L
    J Biol Regul Homeost Agents; 1990; 4(1):25-9. PubMed ID: 2399833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma and tissue pharmacokinetics of human interferon-alpha in the rat after its intravenous administration.
    Greig NH; Soncrant TT; Wozniak KM; Rapoport SI
    J Pharmacol Exp Ther; 1988 May; 245(2):574-80. PubMed ID: 2835475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative pharmacokinetics of a tumour-targeting therapy candidate rh-IFNα2a-NGR with rh-IFNα2a administered intravenously in mice and rats.
    Wang XX; Lu L; Song CL; Qian WN; Zhang SY; Zhang YQ; Wu YJ
    J Pharm Pharmacol; 2013 Apr; 65(4):574-81. PubMed ID: 23488787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of administration route on valproate pharmacokinetics in the rabbit.
    Bourin M; Guenzet J; Thomare P; Kergueris MF; Ortega A; Larousse C
    Fundam Clin Pharmacol; 1991; 5(4):331-9. PubMed ID: 1916614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Roles of sympathetic nervous system in the suppression of cytotoxicity of splenic natural killer cells in the rat.
    Katafuchi T; Take S; Hori T
    J Physiol; 1993 Jun; 465():343-57. PubMed ID: 8229839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of absorption promoters in intranasal administration of human fibroblast interferon as a powder dosage form in rabbits.
    Igawa T; Maitani Y; Machida Y; Nagai T
    Chem Pharm Bull (Tokyo); 1989 Feb; 37(2):418-21. PubMed ID: 2743486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nasal absorption of 17 alpha-ethinyloestradiol in the rat.
    Bawarshi-Nassar RN; Hussain A; Crooks PA
    J Pharm Pharmacol; 1989 Mar; 41(3):214-5. PubMed ID: 2568456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A recombinant human interferon-alpha B/D hybrid with a broad host-range.
    Horisberger MA; de Staritzky K
    J Gen Virol; 1987 Mar; 68 ( Pt 3)():945-8. PubMed ID: 3029315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of 125I-GST-TatdMt, a recombinant fusion protein possessing potent anti-obesity activity, after intravenous, nasal, oral, and subcutaneous administration.
    Shin BS; Kim CH; Lee MN; Hur MW; Lee KC; Youn YS; Yoo SD
    Regul Pept; 2007 Apr; 140(1-2):74-80. PubMed ID: 17175039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficiency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins.
    Khafagy el-S; Morishita M; Kamei N; Eda Y; Ikeno Y; Takayama K
    Int J Pharm; 2009 Oct; 381(1):49-55. PubMed ID: 19646515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human beta-interferon incubated with muscle homogenate is protected by albumin but not by proteinase inhibitors.
    Paulesu L; Pessina GP; Bocci V
    Proc Soc Exp Biol Med; 1992 Jul; 200(3):414-7. PubMed ID: 1615016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides.
    He YL; Murby S; Warhurst G; Gifford L; Walker D; Ayrton J; Eastmond R; Rowland M
    J Pharm Sci; 1998 May; 87(5):626-33. PubMed ID: 9572915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and biodisposition of recombinant human interferon-alpha 2C in rat and marmoset.
    Greischel A; Tanswell P; Busch U; Schumacher K
    Arzneimittelforschung; 1988 Oct; 38(10):1539-43. PubMed ID: 3196399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The lymphatic route--II. Pharmacokinetics of human recombinant interferon-alpha 2 injected with albumin as a retarder in rabbits.
    Bocci V; Muscettola M; Naldini A; Bianchi E; Segre G
    Gen Pharmacol; 1986; 17(1):93-6. PubMed ID: 3949153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety pharmacology, toxicology and pharmacokinetic assessment of recombinant human omega-interferon produced from CHO-SS cells.
    Buckwold VE; Lang W; Scribner C; Blanchett D; Alessi T; Langecker P
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):62-70. PubMed ID: 16867173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacokinetics of human interferons].
    Furue H; Kobayashi H; Komuro T; Kako M; Mugitani H; Fuse K; Kaise R; Nagai K; Takahashi T; Hirota F
    Gan To Kagaku Ryoho; 1984 Apr; 11(4):935-42. PubMed ID: 6721508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mucosal or systemic administration of rE2 glycoprotein antigen loaded PLGA microspheres.
    Brandhonneur N; Loizel C; Chevanne F; Wakeley P; Jestin A; Le Potier MF; Le Corre P
    Int J Pharm; 2009 May; 373(1-2):16-23. PubMed ID: 19429284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oromucosal interferon therapy: pharmacokinetics and pharmacodynamics.
    Eid P; Meritet JF; Maury C; Lasfar A; Weill D; Tovey MG
    J Interferon Cytokine Res; 1999 Feb; 19(2):157-69. PubMed ID: 10090401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.